Intrathecal IGF2 siRNA injection provides long-lasting anti-allodynic effect in a spared nerve injury rat model of neuropathic pain

PLoS One. 2021 Dec 2;16(12):e0260887. doi: 10.1371/journal.pone.0260887. eCollection 2021.

Abstract

Previous studies have shown an increase of insulin-like growth factor-2 (IGF2) in animal models of neuropathic pain. We aimed to examine the hypothesis that reducing the expression of IGF2 using intrathecal IGF2 small-interfering RNA (siRNA) would attenuate the development of neuropathic pain in rats after spared nerve injury (SNI). Male Wistar rats were divided into three groups: sham-operated group, in which surgery was performed to cut the muscles without injuring the nerves; SNI group, in which SNI surgery was performed to sever the nerves; and SNI + siRNA IGF2 group, in which SNI surgery was performed, and IGF2-siRNA was administered intrathecally 1 day after SNI. The rats were assessed for mechanical allodynia and cold allodynia 1 day before surgery (baseline), and at 2, 4, 6, 8, and 10 days after siRNA treatment. The rat spinal cord was collected for quantitative polymerase chain reaction and western blot analysis. Compared with the SNI group, rats that received IGF2 siRNA showed a significantly increased SNI-induced paw-withdrawal threshold to metal filament stimulation from Day 4 to Day 10 after SNI surgery. IGF2 siRNA significantly decreased the response duration from the acetone test from Day 2 to Day 10 following SNI surgery. SNI increased IGF2 mRNA expression on Day 2 and increased IGF2 protein expression on Day 8 and Day 10 in the spinal cord of the SNI rats. However, the above-mentioned effects of IGF2 mRNA and protein expression were significantly inhibited in the SNI + IGF2 siRNA group. We demonstrated that intrathecal administration of IGF2 siRNA provided significant inhibition of SNI-induced neuropathic pain via inhibition of IGF2 expression in the spinal cord. The analgesic effect lasted for 10 days. Further exploration of intrathecal IGF2 siRNA administration as a potential therapeutic strategy for neuropathic pain is warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal*
  • Hyperalgesia / etiology
  • Hyperalgesia / metabolism
  • Hyperalgesia / pathology
  • Hyperalgesia / therapy*
  • Injections, Spinal
  • Insulin-Like Growth Factor II / antagonists & inhibitors*
  • Insulin-Like Growth Factor II / genetics
  • Male
  • Neuralgia / etiology
  • Neuralgia / metabolism
  • Neuralgia / pathology
  • Neuralgia / therapy*
  • Peripheral Nerve Injuries / complications*
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / genetics
  • Rats
  • Rats, Wistar

Substances

  • Igf2 protein, rat
  • RNA, Small Interfering
  • Insulin-Like Growth Factor II

Grants and funding

This work was supported by the Ministry of Science and Technology (MOST), R.O.C, program grants for applied research, grant number: MOST 108-2314-016-028. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.